Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives

Abstract

Breast cancer continues to be the primary cause of cancer-related deaths among women globally, with increased rates of incidence and mortality, highlighting the critical need for effective treatment strategies. Recent developments have introduced a variety of treatment options that address the molecular diversity of breast cancer; nonetheless, drug resistance remains a significant barrier to achieving favorable results. This review explains the crucial role of genetic and epigenetic changes in contributing to therapeutic resistance, in addition to other factors such as increased drug efflux, enhanced DNA repair, evasion of senescence, tumor heterogeneity, the tumor microenvironment (TME), and epithelial-to-mesenchymal transition (EMT). Genetic modifications, including mutations in oncogenes and tumor suppressor genes, disrupt essential signaling pathways, facilitating resistance to chemotherapy and targeted therapies. At the same time, epigenetic modifications - like DNA methylation, alterations to histones, and dysregulation of non-coding RNAs - reprogram gene expression, supporting adaptive resistance mechanisms. These molecular abnormalities contribute to the plasticity of tumors, allowing cancer cells to evade therapeutic approaches. This review consolidates recent discoveries regarding how these genetic and epigenetic modifications affect treatment responses and resistance in breast cancer, highlighting their interaction with disease advancement. By pinpointing new drug targets, including immunotherapeutic strategies, this article seeks to shed light on the molecular underpinnings of chemoresistance, aiding in the refinement of existing treatment protocols. A more profound understanding of these mechanisms offers the potential for developing precision therapies to overcome resistance, reduce relapse rates, and improve clinical outcomes for breast cancer patients.

Keywords

Breast cancer / drug resistance / genetic mutations / epigenetic factors / biomarkers / immunotherapeutics

References

[1] Giaquinto AN,Newman LA.Breast cancer statistics 2024.CA Cancer J Clin2024;74:477-95

[2] Zhao H.The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.Breast Cancer2021;28:187-95

[3] Łukasiewicz S,Forma A,Sitarz R.Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review.Cancers2021;13:4287 PMCID:PMC8428369

[4] Arps DP,Zhao L,Pang JC.Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.Breast Cancer Res Treat2013;138:719-26 PMCID:PMC3906642

[5] Waks AG.Breast cancer treatment: a review.JAMA2019;321:288-300

[6] Mandapati A.Triple negative breast cancer: approved treatment options and their mechanisms of action.J Cancer Res Clin Oncol2023;149:3701-19 PMCID:PMC10314854

[7] Nikolaou M,Georgakilas AG.The challenge of drug resistance in cancer treatment: a current overview.Clin Exp Metastasis2018;35:309-18

[8] Bhushan A,Menon JU.Current state of breast cancer diagnosis, treatment, and theranostics.Pharmaceutics2021;13:723 PMCID:PMC8156889

[9] Hayes DF,Stearns V.Prognostic factors in breast cancer: current and new predictors of metastasis.J Mammary Gland Biol Neoplasia2001;6:375-92

[10] Weigel MT.Current and emerging biomarkers in breast cancer: prognosis and prediction.Endocr Relat Cancer2010;17:R245-62

[11] Zhou Y,Qiu J.Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal Transduct Target Ther2024;9:132 PMCID:PMC11102923

[12] Nalejska E,Lewandowska MA.Prognostic and predictive biomarkers: tools in personalized oncology.Mol Diagn Ther2014;18:273-84 PMCID:PMC4031398

[13] Wu HJ.Recent discoveries of macromolecule- and cell-based biomarkers and therapeutic implications in breast cancer.Int J Mol Sci2021;22:636 PMCID:PMC7827149

[14] Dagogo-Jack I.Tumour heterogeneity and resistance to cancer therapies.Nat Rev Clin Oncol2018;15:81-94

[15] Sun XX.Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment.Acta Pharmacol Sin2015;36:1219-27 PMCID:PMC4648179

[16] Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth.Cancer Cell2023;41:374-403

[17] Lavie D,Erez N.Cancer-associated fibroblasts in the single-cell era.Nat Cancer2022;3:793-807 PMCID:PMC7613625

[18] Butti R.The molecular dialogue between the tumor cells and fibroblasts.Oncotarget2023;14:462-3 PMCID:PMC10197956

[19] Yuan J,Yang L.Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.Breast Cancer Res2015;17:69 PMCID:PMC4453053

[20] Mao Y,Qu Q.Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells.Mol Biosyst2015;11:1029-40

[21] Gao Y,Zeng C.CD63⁺ cancer-associated fibroblasts confer tamoxifen resistance to breast cancer cells through exosomal miR-22.Adv Sci2020;7:2002518 PMCID:PMC7610308

[22] Su S,Yao H.CD10⁺GPR77⁺ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness.Cell2018;172:841-56.e16

[23] Fan G,Tang L.TSPAN8⁺ myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer.Sci Transl Med2024;16:eadj5705

[24] Du R,Lu X.PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.Drug Resist Updat2023;68:100947

[25] Radharani NNV,Nimma R.Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway.Cancer Cell Int2022;22:122 PMCID:PMC8932105

[26] Huang R,Chen S.The role of tumor-associated macrophages in tumor immune evasion.J Cancer Res Clin Oncol2024;150:238 PMCID:PMC11076352

[27] Phi LTH,Yang YG.Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment.Stem Cells Int2018;2018:5416923 PMCID:PMC5850899

[28] Alison MR,Nicholson LJ.Cancer stem cells: problems for therapy?.J Pathol2011;223:147-61

[29] Dean M,Bates S.Tumour stem cells and drug resistance.Nat Rev Cancer2005;5:275-84

[30] Zheng Q,Zhou F,Meng X.The breast cancer stem cells traits and drug resistance.Front Pharmacol2020;11:599965 PMCID:PMC7876385

[31] Bourguignon LY,Xia W.Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.J Biol Chem2008;283:17635-51 PMCID:PMC2427357

[32] Sansone P,Berishaj M.Self-renewal of CD133^hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.Nat Commun2016;7:10442 PMCID:PMC4748123

[33] Wang T,Xiang D.EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to doxorubicin in a breast cancer model.Theranostics2015;5:1456-72 PMCID:PMC4672025

[34] Croker AK.Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.Breast Cancer Res Treat2012;133:75-87

[35] Pal M,Pandey M.Understanding genetic variations associated with familial breast cancer.World J Surg Oncol2024;22:271 PMCID:PMC11465949

[36] Kennedy RD,Mullan PB,Harkin DP.The role of BRCA1 in the cellular response to chemotherapy.J Natl Cancer Inst2004;96:1659-68

[37] Steelman LS,Sokolosky ML.Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.Oncogene2008;27:4086-95 PMCID:PMC3836277

[38] Wu H,Liu Y.Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.J Cancer Res Clin Oncol2012;138:1449-62 PMCID:PMC11824296

[39] Tulsyan S,Mittal B.The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment.Pharmgenomics Pers Med2016;9:47-58 PMCID:PMC4854269

[40] Geisler S,Aas T,Fluge O,Lillehaug JR,Borresen-Dale AL.Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.Cancer Res2001;61:2505-12

[41] Geisler S,Johnsen H,Geisler J,Anker G.TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.Clin Cancer Res2003;9:5582-8

[42] Chrisanthar R,Løkkevik E.CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.PLoS One2008;3:e3062 PMCID:PMC2518116

[43] Hou H,Zhang X.The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors.Cancer Cell Int2019;19:216 PMCID:PMC6704499

[44] Zhang X,Zhang Q.ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM.Cell Death Dis2018;9:57 PMCID:PMC5833408

[45] Prabhu KS,Kuttikrishnan S,Bhat AA.Beyond genetics: exploring the role of epigenetic alterations in breast cancer.Pathol Res Pract2024;254:155174

[46] Roulois D,Singhania R.DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts.Cell2015;162:961-73 PMCID:PMC4843502

[47] Deblois G,Grillo G.Epigenetic switch-induced viral mimicry evasion in chemotherapy-resistant breast cancer.Cancer Discov2020;10:1312-29

[48] Wajapeyee N.Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies.Cancer Res2021;81:5589-95 PMCID:PMC8595782

[49] Yadav M,Sharma A.Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review.Open Biol2024;14:230272 PMCID:PMC11285512

[50] Sukocheva OA,Friedemann M,Hagelgans A.The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: current findings and future perspectives.Semin Cancer Biol2022;82:35-59

[51] Romero-Garcia S,Carlos-Reyes A.Role of DNA methylation in the resistance to therapy in solid tumors.Front Oncol2020;10:1152 PMCID:PMC7426728

[52] Zhang J,Jiang H.ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.Cell Death Dis2017;8:e2732 PMCID:PMC5477580

[53] Chekhun VF,Yurchenko OV.Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.Cancer Lett2006;231:87-93

[54] Ansar M,Hung CS.Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer.Front Oncol2022;12:1004261 PMCID:PMC9676938

[55] Liu HY,Yang F.Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer.Nucleic Acids Res2020;48:3638-56 PMCID:PMC7144926

[56] He DX,Jiang L,Ma X.A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer.Mol Pharmacol2014;86:536-47

[57] Luo F,Sun B.LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling.Mol Cancer2024;23:60 PMCID:PMC10958889

[58] Kumari K,Aguilo F.Regulatory roles of RNA modifications in breast cancer.NAR Cancer2021;3:zcab036 PMCID:PMC8445368

[59] Song H,Dong S.Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications.Signal Transduct Target Ther2020;5:193 PMCID:PMC7479143

[60] Liu X,Dai X.Adenylate kinase 4 modulates the resistance of breast cancer cells to tamoxifen through an m⁶A-based epitranscriptomic mechanism.Mol Ther2020;28:2593-604 PMCID:PMC7704734

[61] Wang J,Zheng J.A1BG-AS1 promotes adriamycin resistance of breast cancer by recruiting IGF2BP2 to upregulate ABCB1 in an m6A-dependent manner.Sci Rep2023;13:20730 PMCID:PMC10676358

[62] Nakano M,Gotoh S.A-to-I RNA editing up-regulates human dihydrofolate reductase in breast cancer.J Biol Chem2017;292:4873-84 PMCID:PMC5377802

[63] Millán-Zambrano G,Bannister AJ.Histone post-translational modifications - cause and consequence of genome function.Nat Rev Genet2022;23:563-80

[64] Mattei AL,Meissner A.DNA methylation: a historical perspective.Trends Genet2022;38:676-707

[65] Zhang G,Wang X.N6-Methyladenosine methylation modification in breast cancer: current insights.J Transl Med2024;22:971 PMCID:PMC11514918

[66] Wang Q,You Z.LncRNA TINCR favors tumorigenesis via STAT3-TINCR-EGFR-feedback loop by recruiting DNMT1 and acting as a competing endogenous RNA in human breast cancer.Cell Death Dis2021;12:83 PMCID:PMC7809450

[67] Wang Q,Ma X.LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis.Cell Death Dis2023;14:76 PMCID:PMC9892521

[68] Wang J,Yang J.The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.J Hematol Oncol2019;12:81 PMCID:PMC6657081

[69] He DX.Transient receptor potential channel C5 in cancer chemoresistance.Acta Pharmacol Sin2016;37:19-24 PMCID:PMC4722981

[70] Pan T,Jin L.DNMT1-mediated demethylation of lncRNA MEG3 promoter suppressed breast cancer progression by repressing Notch1 signaling pathway.Cell Cycle2022;21:2323-37 PMCID:PMC9586644

[71] Huang ZF,Shen ZL,Gao K.UXT, a novel DNMT3b-binding protein, promotes breast cancer progression via negatively modulating lncRNA MEG3/p53 axis.Mol Ther Oncolytics2022;24:497-506 PMCID:PMC8850569

[72] Si X,Zhang E.LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK.Oncotarget2016;7:81452-62 PMCID:PMC5348405

[73] Tian Y,Wu P.MIR497HG-derived miR-195 and miR-497 mediate tamoxifen resistance via PI3K/AKT signaling in breast cancer.Adv Sci2023;10:e2204819 PMCID:PMC10131819

[74] Cai Y,Xu D.M6A RNA methylation-mediated dysregulation of AGAP2-AS1 promotes trastuzumab resistance of breast cancer.Pharmacology2024;109:282-92

[75] Zhang H,Liu C,Wang X.Interactions between long non-coding RNAs and m6 A modification in cancer.Discov Oncol2025;16:579 PMCID:PMC12009795

[76] Liu X,Sui C.Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: mechanisms and clinical implications.Int J Cancer2024;154:1877-89

[77] Wang D,Peng L.Crosstalk between N6-methyladenosine (m6A) modification and noncoding RNA in tumor microenvironment.Int J Biol Sci2023;19:2198-219 PMCID:PMC10158024

[78] Chen T,Luo P.Crosstalk between m6A modification and autophagy in cancer.Cell Biosci2024;14:44 PMCID:PMC10996158

[79] Klinge CM,Tooley CS.HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.Sci Rep2019;9:9430 PMCID:PMC6603045

[80] Wu Y,Cenciarini ME.Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis.Cancer Res2018;78:671-84 PMCID:PMC5967248

[81] Kim MR,Zhang Y,Chang CJ.TET2 directs mammary luminal cell differentiation and endocrine response.Nat Commun2020;11:4642 PMCID:PMC7493981

[82] Oh JH,Kim KH.Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.Cancer Lett2020;495:145-55

[83] Boulding T,Tan A.LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.Sci Rep2018;8:73 PMCID:PMC5758711

[84] Choi HJ,Won HY.Role of RBP2-induced ER and IGF1R-ErbB signaling in tamoxifen resistance in breast cancer.J Natl Cancer Inst2018;110:400-10

[85] Zhou Q,Liu X,Miao L.Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3β/p53 activation.Cancer Manag Res2019;11:625-36 PMCID:PMC6331075

[86] Kaboli PJ,Ismail P.MicroRNA-based therapy and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment.Pharmacol Res2015;97:104-21

[87] Kaboli PJ,Jomhori M.Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.Am J Cancer Res2021;11:5155-83

[88] Li Y,Li H,Huang Y.Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells.Chem Biol Interact2019;305:98-104

[89] Qian J,Liu W.Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.Eur J Pharmacol2019;852:231-43

[90] McGlynn LM,Edwards J.Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients.Clin Cancer Res2009;15:1487-95

[91] Saatci O,Sahin O.Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.J Mol Med2021;99:1691-710 PMCID:PMC8611518

[92] Bai WD,Zhang MY.MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.Int J Cancer2014;135:1356-68

[93] Palomeras S,Viñas G.Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.Breast Cancer Res2019;21:79 PMCID:PMC6612099

[94] Bartucci M,Moriconi C.TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.Oncogene2015;34:681-90

[95] Donninger H,Clark GJ.The RASSF1A tumor suppressor.J Cell Sci2007;120:3163-72

[96] Zeng R.The Hippo signaling pathway in drug resistance in cancer.Cancers2021;13:318 PMCID:PMC7830227

[97] Liu L,Lee DH,Pfeifer GP.Control of microtubule stability by the RASSF1A tumor suppressor.Oncogene2003;22:8125-36

[98] Er I.Hedgehog pathway is a regulator of stemness in HER2-positive trastuzumab-resistant breast cancer.Int J Mol Sci2024;25:12102 PMCID:PMC11594134

[99] Wils LJ.Epigenetic regulation of the Hedgehog and Wnt pathways in cancer.Crit Rev Oncol Hematol2018;121:23-44

[100] Gyamfi J,Eom M.Author Correction: Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells.Sci Rep2020;10:13049 PMCID:PMC7387482

[101] Xing J,Fu L,Guan J.SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.Cancer Med2019;8:7086-97 PMCID:PMC6853819

[102] Kettner NM,Durak MG.Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer.Clin Cancer Res2019;25:3996-4013 PMCID:PMC6606366

[103] Xiang S,Hoffman AE.Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.J Pineal Res2019;67:e12586 PMCID:PMC6750268

[104] Ye L,Wang X.Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer.EMBO Mol Med2019;11:e10638 PMCID:PMC8899907

[105] Garcia-Martinez L,Nakata Y,Morey L.Epigenetic mechanisms in breast cancer therapy and resistance.Nat Commun2021;12:1786 PMCID:PMC7979820

[106] O’Brien CS,Farnie G.Resistance to endocrine therapy: are breast cancer stem cells the culprits?.J Mammary Gland Biol Neoplasia2009;14:45-54

[107] Butti R,Gunasekaran VP,Kumar D.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.Mol Cancer2018;17:34 PMCID:PMC5817867

[108] Nami B,Black C.Epigenetic silencing of HER2 expression during epithelial-mesenchymal transition leads to trastuzumab resistance in breast cancer.Life2021;11:868 PMCID:PMC8472246

[109] Jackson SP.The DNA-damage response in human biology and disease.Nature2009;461:1071-8 PMCID:PMC2906700

[110] Jurkovicova D,Gašparović AČ.DNA damage response in cancer therapy and resistance: challenges and opportunities.Int J Mol Sci2022;23:14672 PMCID:PMC9735783

[111] Wang S,Luo X,Chang H.LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer.Oncogene2018;37:3243-59

[112] Tu X,Zhou Q.ATR inhibition is a promising radiosensitizing strategy for triple-negative breast cancer.Mol Cancer Ther2018;17:2462-72 PMCID:PMC6215494

[113] Luo M.Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone.Anticancer Res2004;24:2127-34

[114] Neophytou CM,Erin N.Apoptosis deregulation and the development of cancer multi-drug resistance.Cancers2021;13:4363 PMCID:PMC8430856

[115] Abbas R.Targeting XIAP for promoting cancer cell death-the story of ARTS and SMAC.Cells2020;9:663 PMCID:PMC7140716

[116] Ozaki T.Role of p53 in cell death and human cancers.Cancers2011;3:994-1013 PMCID:PMC3756401

[117] Du K.CREB is a regulatory target for the protein kinase Akt/PKB.J Biol Chem1998;273:32377-9

[118] Liu R,Liu G.PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.Cell Death Dis2020;11:797 PMCID:PMC7515865

[119] Safa AR.Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces.Cancer Drug Resist2022;5:850-72 PMCID:PMC9771762

[120] Breunig C,Küblbeck M.MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells.Cell Death Dis2017;8:e2973 PMCID:PMC5596553

[121] Sun WL,Gan TQ.Autophagy facilitates multidrug resistance development through inhibition of apoptosis in breast cancer cells.Neoplasma2015;62:199-208

[122] Townsend PA,Cexus ONF,Soond SM.BH3-mimetics: recent developments in cancer therapy.J Exp Clin Cancer Res2021;40:355 PMCID:PMC8576916

[123] Bose P,Konopleva M.Pathways and mechanisms of venetoclax resistance.Leuk Lymphoma2017;58:1-17 PMCID:PMC5478500

[124] Neizer-Ashun F.Reality CHEK: understanding the biology and clinical potential of CHK1.Cancer Lett2021;497:202-11

[125] Fuino L,Wittmann S,Guo F,Wang HG,Bhalla K.Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.Mol Cancer Ther2003;2:971-84

[126] Li ZH,Xiong QY.miR-34a expression in human breast cancer is associated with drug resistance.Oncotarget2017;8:106270-82 PMCID:PMC5739732

[127] Yang R,Schott S.The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies.Carcinogenesis2017;38:312-20

[128] Hannafon BN,Calloway CL.Plasma exosome microRNAs are indicative of breast cancer.Breast Cancer Res2016;18:90 PMCID:PMC5016889

[129] Iliopoulos D,Hirsch HA,Struhl K.STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer.Mol Cell2010;39:493-506 PMCID:PMC2929389

[130] Iorio MV,Liu CG.MicroRNA gene expression deregulation in human breast cancer.Cancer Res2005;65:7065-70

[131] Han Y,Sun T.Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer.Signal Transduct Target Ther2023;8:429 PMCID:PMC10654734

[132] Lei JH,Wang Z.FGFR2-BRD4 axis regulates transcriptional networks of histone 3 modification and synergy between its inhibitors and PD-1/PD-L1 in a TNBC mouse model.Front Immunol2022;13:861221 PMCID:PMC9084888

[133] Voulgarelis D,Herencia Ropero A.Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers.NPJ Precis Oncol2024;8:266 PMCID:PMC11574300

[134] Sha LY,Wang W,Liu SK,Zhang H.MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.Eur Rev Med Pharmacol Sci2016;20:2201-8

[135] Nair MG,Korlimarla A.miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis.Cancer Med2020;9:5587-97 PMCID:PMC7402845

[136] Ling Y,Lin Q.circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.Mol Cancer2022;21:8 PMCID:PMC8722291

[137] Siouda M,Barbollat-Boutrand L.CDYL2 epigenetically regulates MIR124 to control NF-κB/STAT3-dependent breast cancer cell plasticity.iScience2020;23:101141 PMCID:PMC7251929

[138] Chen Y,Gong D.ACLY: a biomarker of recurrence in breast cancer.Pathol Res Pract2020;216:153076

[139] Chen D,Yang M.H3K36me2 methyltransferase NSD2/WHSC1 promotes triple-negative breast cancer metastasis via activation of ULK1-dependent autophagy.Autophagy2025;1-19

[140] Gökmen-Polar Y,Goswami CP.Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer.Mod Pathol2015;28:677-85

[141] Guertin DA.Acetyl-CoA metabolism in cancer.Nat Rev Cancer2023;23:156-72 PMCID:PMC11137663

[142] Filipits M, Rudas M, Heinzl H, et al; Austrian Breast and Colorectal Cancer Study Group. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res. 2009;15:5888-94.

[143] Kim GJ,Min KW,Oh YH.Loss of p27(kip1) expression is associated with poor prognosis in patients with taxane-treated breast cancer.Pathol Res Pract2018;214:565-71

[144] Wang J,Yuan P.TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.Breast Cancer Res Treat2012;135:531-7

[145] Di Leo A, Desmedt C, Bartlett JM, et al; HER2/TOP2A Meta-analysis Study Group. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011;12:1134-42.

[146] Ginzac A,Durando X.Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.Breast Cancer Res Treat2024;205:267-79 PMCID:PMC11101498

[147] Slamon DJ,Shak S.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med2001;344:783-92

[148] Parkes EE, Savage KI, Lioe T, et al; Neo-DDIR Investigators. Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. Br J Cancer. 2022;126:247-58. PMCID:PMC8770594

[149] Cai R,Zhao D.A high immune-related index with the suppression of cGAS-STING pathway is a key determinant to herceptin resistance in HER2+ breast cancer.Int J Biol Sci2024;20:3497-514 PMCID:PMC11234227

[150] Li H,Wei Y.SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane.J Exp Clin Cancer Res2020;39:81 PMCID:PMC7204297

[151] Chen YC,Liang JL.CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.Oncotarget2017;8:29699-710 PMCID:PMC5444696

[152] Klintman M.Early surrogate markers of treatment activity: where are we now?.J Natl Cancer Inst Monogr2015;2015:24-8

[153] Elzawahry HM,Mokhtar NM,Ismail YM.Role of Ki67 in predicting resistance to adjuvant tamoxifen in postmenopausal breast cancer patients.J Egypt Natl Canc Inst2013;25:181-91

[154] Srivastava TP,Goel I.Prognostic role of androgen receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer.BMC Cancer2024;24:1398 PMCID:PMC11562864

[155] Warmoes M,Xu G.Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.Mol Cell Proteomics2013;12:1319-34 PMCID:PMC3650342

[156] Al-Bahlani S,Al-Adawi M,Al-Dhahli B.Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis.Apoptosis2017;22:865-76

[157] Sardesai SD,Gallagher C.Inhibiting fatty acid synthase with omeprazole to improve efficacy of neoadjuvant chemotherapy in patients with operable TNBC.Clin Cancer Res2021;27:5810-7

[158] Tutt ANJ, Garber JE, Kaufman B, et al; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-405. PMCID:PMC9126186

[159] Li K,Li H.SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2- breast cancer.Cell Death Dis2024;15:444 PMCID:PMC11196642

[160] Finn RS,Rugo HS.Palbociclib and letrozole in advanced breast cancer.N Engl J Med2016;375:1925-36

[161] Denkert C,Schneeweiss A.Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.Lancet Oncol2021;22:1151-61

[162] Grote I,Kandt L.TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.Cancer Med2021;10:8581-94 PMCID:PMC8633262

[163] Miles DW,Dirix LY.Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.J Clin Oncol2010;28:3239-47

[164] Haddad TC,Suman V.Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.Breast Cancer Res Treat2018;168:639-47 PMCID:PMC5842248

[165] Park YH,Park K.Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.Genome Med2023;15:55 PMCID:PMC10360358

[166] Rezaei Z,Allahyari A.Plasma microRNA-195, -34c, and -1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.Toxicol Appl Pharmacol2023;475:116652

[167] Wang ZH,Jia SC.Trastuzumab resistance in HER2-positive breast cancer: mechanisms, emerging biomarkers and targeting agents.Front Oncol2022;12:1006429 PMCID:PMC9584623

[168] Zhang Z,Yu G.Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.Cancer Chemother Pharmacol2020;86:761-72

[169] Luengo-Gil G,Chaves-Benito A.Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.Cell Oncol2019;42:627-44

[170] Huang W,Xiang S.Regulatory mechanism of miR-20a-5p expression in cancer.Cell Death Discov2022;8:262 PMCID:PMC9110721

[171] Pajic M,Daly S.miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense.Cancer Res2018;78:501-15

[172] Zou X,Li M.MicroRNA profiling in serum: potential signatures for breast cancer diagnosis.Cancer Biomark2021;30:41-53

[173] Cun J.Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells.Biomed Pharmacother2018;107:117-28

[174] Xiong H,Wang T.Photoswitchable dynamics and RNAi synergist with tailored interface and controlled release reprogramming tumor immunosuppressive niche.Biomaterials2025;312:122712

[175] Kassem NM,Kassem HA.Circulating miR-34a and miR-125b as promising non invasive biomarkers in egyptian locally advanced breast cancer patients.Asian Pac J Cancer Prev2019;20:2749-55 PMCID:PMC6976833

[176] Hoppe R,Winter S.Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.Eur J Cancer2013;49:3598-608

[177] Kahraman M,Laufer T.MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer.Sci Rep2018;8:11584 PMCID:PMC6072710

[178] Liao B,Xie Y,Min J.LINK-A: unveiling its functional role and clinical significance in human tumors.Front Cell Dev Biol2024;12:1354726 PMCID:PMC11032015

[179] Lin A,Li C.The LINK-A lncRNA interacts with PtdIns(3,4,5)P₃ to hyperactivate AKT and confer resistance to AKT inhibitors.Nat Cell Biol2017;19:238-51 PMCID:PMC5332298

[180] Li W,Wang H.Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.Oncotarget2016;7:27778-86 PMCID:PMC5053687

[181] Sun Z,Wang T,Tian X.Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer.J Cancer Res Ther2019;15:933-40

[182] Li D,Niu X.Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.Cancer Sci2020;111:47-58 PMCID:PMC6942430

[183] Niu X,Li J.Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization.Cell Death Dis2021;12:509 PMCID:PMC8131586

[184] Castellaro AM,Di Tada CE.Tumor-associated macrophages induce endocrine therapy resistance in ER+ breast cancer cells.Cancers2019;11:189 PMCID:PMC6406935

[185] Liu H,Zhang M.Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.Breast Cancer Res Treat2017;166:95-107

[186] Gelsomino L,Camera G.Leptin signaling contributes to aromatase inhibitor resistant breast cancer cell growth and activation of macrophages.Biomolecules2020;10:543 PMCID:PMC7226081

[187] Dong X,Wang J.Glutathione S-transferases P1-mediated interleukin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer.Biochem Pharmacol2020;182:114289

[188] Chen WX,Zhu B.Exosomal miR-222 from adriamycin-resistant MCF-7 breast cancer cells promote macrophages M2 polarization via PTEN/Akt to induce tumor progression.Aging2021;13:10415-30 PMCID:PMC8064228

[189] Emami F,Nguyen TT.Photoimmunotherapy with cetuximab-conjugated gold nanorods reduces drug resistance in triple negative breast cancer spheroids with enhanced infiltration of tumor-associated macrophages.J Control Release2021;329:645-64

[190] Yang C,He P.Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway.Med Oncol2015;32:352

[191] Ireland L,Campbell F.Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.Oncogene2018;37:2022-36 PMCID:PMC5895608

[192] Walker ND,Guiro K.Exosomes from differentially activated macrophages influence dormancy or resurgence of breast cancer cells within bone marrow stroma.Cell Death Dis2019;10:59 PMCID:PMC6347644

[193] Ahmed S,El-Husseiny N.IL-8 secreted by tumor associated macrophages contribute to lapatinib resistance in HER2-positive locally advanced breast cancer via activation of Src/STAT3/ERK1/2-mediated EGFR signaling.Biochim Biophys Acta Mol Cell Res2021;1868:118995

[194] Hu X,Zhang X.The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.Neoplasia2020;22:539-53 PMCID:PMC7509589

[195] Usman MW,Zheng T.Author Correction: Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling.Cell Death Dis2019;10:501 PMCID:PMC6591411

[196] Usman MW,Zheng T.Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling.Cell Death Dis2018;9:809 PMCID:PMC6057974

[197] Jiang Z,Yan M.TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.J Clin Invest2021;131:139434 PMCID:PMC8262501

[198] Ekiz HA,Gundlapalli H,Williams MA.Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.Oncoimmunology2018;7:e1480286 PMCID:PMC6140584

[199] Zheng G,Li W.Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.Signal Transduct Target Ther2021;6:236 PMCID:PMC8219715

[200] Garcia-Chagollan M,Carranza-Rosales P.Expression of NK cell surface receptors in breast cancer tissue as predictors of resistance to antineoplastic treatment.Technol Cancer Res Treat2018;17:1533033818764499 PMCID:PMC5882046

[201] Wang S,Yao M,Wang W.Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.Biochem Biophys Res Commun2018;503:1605-9

[202] Merrouche Y,Cure H.IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.Oncotarget2016;7:53350-61 PMCID:PMC5288192

[203] Maniati E,Hagemann T.Up for Mischief? IL-17/Th17 in the tumour microenvironment.Oncogene2010;29:5653-62 PMCID:PMC2962667

[204] Gunnarsdóttir FB,Bergenfelz C.Inflammatory macrophage derived TNFα downregulates estrogen receptor α via FOXO3a inactivation in human breast cancer cells.Exp Cell Res2020;390:111932

[205] Xuan QJ,Nanding A.Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients.Pathol Oncol Res2014;20:619-24

[206] Xing Z,Liu J,Feng K.LINC00337 induces tumor development and chemoresistance to paclitaxel of breast cancer by recruiting M2 tumor-associated macrophages.Mol Immunol2021;138:1-9

[207] Mehta AK,Hartl CA.Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.Nat Cancer2021;2:66-82 PMCID:PMC7963404

[208] Liu Y,Kang N.Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer.Cell Death Dis2020;11:993 PMCID:PMC7678839

[209] Tripathi C,Kanchan RK.Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin.Oncotarget2014;5:5350-68 PMCID:PMC4170629

[210] Zhang C,Cai Y.Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model.Biomaterials2016;84:1-12

[211] Nagano M,Kozuka Y.CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression.Oncol Lett2021;21:36 PMCID:PMC7693484

[212] Qiao J,Mi Y.Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.Biochem Pharmacol2020;180:114126

[213] Qin J,Tan B.Blocking P2X7-mediated macrophage polarization overcomes treatment resistance in lung cancer.Cancer Immunol Res2020;8:1426-39

[214] Tan B,Zhang J.Inhibition of Rspo-Lgr4 facilitates checkpoint blockade therapy by switching macrophage polarization.Cancer Res2018;78:4929-42

[215] Yang YL,Huang ZQ.T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems.Front Immunol2023;14:1199173 PMCID:PMC10348220

[216] Li R.The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy.Front Immunol2023;14:1194020 PMCID:PMC10233026

[217] Wu X,Jiang R,Guo H.Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects.Mol Cancer2023;22:194 PMCID:PMC10693139

[218] Zheng Y,Tang H,Zheng Q.Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer.Front Immunol2023;14:1153990 PMCID:PMC10327275

[219] Jorgovanovic D,Wang L.Roles of IFN-γ in tumor progression and regression: a review.Biomark Res2020;8:49 PMCID:PMC7526126

[220] Lin X,Chen P.Regulatory mechanisms of PD-1/PD-L1 in cancers.Mol Cancer2024;23:108 PMCID:PMC11102195

[221] Nair R,Kuriakose A.Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies.Front Immunol2025;16:1548234 PMCID:PMC11996672

[222] He S,Qi C.Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.Mol Cancer2025;24:5 PMCID:PMC11707952

[223] Padmanabhan R,Meskin N,Al Moustafa AE.Crosstalk between HER2 and PD-1/PD-L1 in breast cancer: from clinical applications to mathematical models.Cancers2020;12:636 PMCID:PMC7139939

[224] Wan W,Chen Q.METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N⁶-methyladenosine modification of PD-L1 mRNA in breast cancer.Mol Cancer2022;21:60 PMCID:PMC8864846

[225] Ji Q,Hao M,Huang J.Immune checkpoint inhibitors combined with chemotherapy compared with chemotherapy alone for triple-negative breast cancer: a systematic review and meta-analysis.Front Oncol2021;11:795650 PMCID:PMC8716854

[226] Li C,Wei S,Wang J.Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.Mol Cancer2020;19:116 PMCID:PMC7367382

[227] Esquivel-Velázquez M,Palacios-Arreola MI,Castro JI.The role of cytokines in breast cancer development and progression.J Interferon Cytokine Res2015;35:1-16 PMCID:PMC4291218

[228] Zhang S,Yi Y.Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.Signal Transduct Target Ther2024;9:149 PMCID:PMC11189549

[229] Han Y,Li L.PD-1/PD-L1 pathway: current researches in cancer.Am J Cancer Res2020;10:727-42 PMCID:PMC7136921

[230] De Bousser E, Meuris L, Callewaert N, Festjens N. Human T cell glycosylation and implications on immune therapy for cancer.Hum Vaccin Immunother2020;16:2374-88 PMCID:PMC7644206

[231] Chen N,Tano Z.CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy.Oncoimmunology2017;6:e1273302 PMCID:PMC5353939

[232] Cheng K,Chai Z.4-1BB-based CAR T cells effectively reverse exhaustion and enhance the anti-tumor immune response through autocrine PD-L1 scFv antibody.Int J Mol Sci2023;24:4197 PMCID:PMC9961031

[233] Hu W,Jin Y.CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.Cancer Immunol Immunother2019;68:365-77 PMCID:PMC11028344

[234] Loi S,Piette F.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.J Clin Oncol2013;31:860-7

[235] Gautam N,Champion N,Czerniecki BJ.Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development.Mol Aspects Med2024;95:101239

[236] Casado-Pelaez M,Esteller M.Single cell cancer epigenetics.Trends Cancer2022;8:820-38

[237] Pont M,Sorolla MA.Applications of CRISPR technology to breast cancer and triple negative breast cancer research.Cancers2023;15:4364 PMCID:PMC10486929

[238] Karn V,Hsu W.CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope.Cancer Cell Int2022;22:234 PMCID:PMC9316746

[239] Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91. PMCID:PMC5125250

[240] Connolly RM,Miller KD.E2112: randomized Phase III Trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. A Trial of the ECOG-ACRIN Cancer Research Group.J Clin Oncol2021;39:3171-81 PMCID:PMC8478386

[241] Li H,Guzzetta AA.Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.Oncotarget2014;5:587-98 PMCID:PMC3996658

[242] Freedman RA,Li T.Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022.Ann Oncol2024;35:993-1002

[243] Vaz Batista M,Cortez P.Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.ESMO Open2024;9:103699 PMCID:PMC11415677

[244] Lum LG,Deol A.Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.J Immunother Cancer2021;9:e002194 PMCID:PMC8202097

[245] Tolaney SM,Neven P.Correction: Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant.Clin Cancer Res2022;28:4587

[246] Jhaveri K,Shah PD.A phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer.Clin Cancer Res2021;27:3867-75 PMCID:PMC8282678

[247] Lu Q,Lee K.Bicalutamide plus aromatase inhibitor in patients with estrogen receptor-positive/androgen receptor-positive advanced breast cancer.Oncologist2020;25:21-e15 PMCID:PMC6964139

[248] Brown LJ,Portman N,Stirzaker C.Epigenetic therapies and biomarkers in breast cancer.Cancers2022;14:474 PMCID:PMC8833457

[249] Fountzilas E,Vo HH.Clinical trial design in the era of precision medicine.Genome Med2022;14:101 PMCID:PMC9428375

[250] Ren L,Wang C.Single cell RNA sequencing for breast cancer: present and future.Cell Death Discov2021;7:104 PMCID:PMC8121804

[251] Li M,Wang M,Wei Y.Advances in single-cell sequencing technology and its applications in triple-negative breast cancer.Breast Cancer2022;14:465-74 PMCID:PMC9760048

[252] Chung W,Lee HO.Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.Nat Commun2017;8:15081 PMCID:PMC5424158

[253] Kim C,Sei E.Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing.Cell2018;173:879-93.e13 PMCID:PMC6132060

[254] Wang Q,Golomb SM.Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer.Nat Commun2019;10:3817 PMCID:PMC6707314

[255] Xu K,Xie H.Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis.Oncogenesis2021;10:66 PMCID:PMC8492772

[256] Vishnubalaji R.Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq.Mol Ther Oncolytics2021;23:151-62 PMCID:PMC8517543

[257] Mao Y,Huang Q.Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges.Mol Cancer2025;24:123 PMCID:PMC12016295

[258] Yu J,Feng Y.Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation.Cancer Drug Resist2025;8:21 PMCID:PMC12059482

[259] Butti R,Bhadauriya G.Development and characterization of a patient-derived orthotopic xenograft of therapy-resistant breast cancer.Oncol Rep2023;49:99 PMCID:PMC10091080

[260] Heater NK,Lu J.Current and future immunotherapy for breast cancer.J Hematol Oncol2024;17:131 PMCID:PMC11670461

[261] Saadi W,Pallardó FV,Mena-Molla S.Long non-coding RNAs as epigenetic regulators of immune checkpoints in cancer immunity.Cancers2022;15:184 PMCID:PMC9819025

[262] Grillone K,Luciano F.A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer.J Transl Med2024;22:731 PMCID:PMC11301835

[263] Tom VV,Mallick S.Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review.Naunyn Schmiedebergs Arch Pharmacol2025;

[264] Liu D,Zhao X.A comprehensive review on targeting diverse immune cells for anticancer therapy: beyond immune checkpoint inhibitors.Crit Rev Oncol Hematol2025;210:104702

[265] Xiong X,Liu CC,Yu KD.Deciphering breast cancer dynamics: insights from single-cell and spatial profiling in the multi-omics era.Biomark Res2024;12:107 PMCID:PMC11411917

[266] Agrawal T,Mishra A,Rakshit T.Epigenetic modifier drug valproic acid enhances cancer metaphase chromosome elasticity and electron transport: an atomic force microscopy approach.JACS Au2025;5:766-78 PMCID:PMC11862959